AXS-05

42 stories · following the connections

Business

Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression

By Nasdaq OMXMar 17, 2016, 11:00 AM UTC

Business

Axsome Therapeutics to Present at the 2016 BIO CEO & Investor Conference

By Nasdaq OMXFeb 1, 2016, 12:00 PM UTC